Literature DB >> 18040247

Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control.

Jose S Pulido1, Sophie J Bakri, Tibor Valyi-Nagy, Deepak Shukla.   

Abstract

PURPOSE: To assess whether intravitreal rituximab 1 mg/0.1 cc penetrates the retina of Dutch-belted rabbits.
METHODS: Two right eyes of two rabbits were injected with intravitreal rituximab 1 mg/0.1 mL, and one right eye of one rabbit was injected with intravitreal tissue plasminogen activator (tPA) 12.5 microg/0.1 mL, as a protein control. The three left eyes received no intravitreal injections. The rabbits were killed; the eyes were enucleated and immediately frozen at -80 degrees C. Rituximab was detected using rabbit antihuman IgG (whole molecule) peroxidase conjugated antibody. tPA was detected using an antihuman IgG with a sheep antihuman tPA antibody conjugated with peroxidase.
RESULTS: There was staining in all retinal layers of the two eyes injected with intravitreal rituximab, and no staining of the retina in the eye injected with intravitreal tPA. The three control eyes showed no staining in any retinal layer.
CONCLUSION: Intravitreal rituximab at a dose of 1 mg/0.1 cc penetrates the retina of Dutch-belted rabbits while the control intravitreal tPA at a dose of 12.5 microg/0.1 cc does not.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040247     DOI: 10.1097/IAE.0b013e31804ac032

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

Authors:  James L Rubenstein; Patrick A Treseler; Paul J Stewart
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 2.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

3.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

4.  More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Authors:  Jose S Pulido; Jose E Pulido; Clement J Michet; Richard G Vile
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

5.  Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

Authors:  James L Rubenstein; Jing Li; Lingjing Chen; Ranjana Advani; Jan Drappatz; Elizabeth Gerstner; Tracy Batchelor; Hendrikus Krouwer; James Hwang; Glenna Auerback; Cigall Kadoch; Clifford Lowell; Pamela Munster; Soonmee Cha; Marc A Shuman; Lloyd E Damon
Journal:  Blood       Date:  2012-11-29       Impact factor: 22.113

6.  Successful Resolution of Preretinal Haemorrhage with Intravitreal Ranibizumab.

Authors:  Baharuddin Noorlaila; Embong Zunaina; Mohd-Noor Raja-Azmi
Journal:  Case Rep Ophthalmol Med       Date:  2016-10-09

7.  Intravitreal ranibizumab in treating extensive traumatic submacular hemorrhage.

Authors:  Ismail Abdul-Salim; Zunaina Embong; Sonny-Teo Khairy-Shamel; Mohd-Noor Raja-Azmi
Journal:  Clin Ophthalmol       Date:  2013-04-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.